典型文献
Adjuvant tamoxifen switched to exemestane treatment in postmenopausal women with estrogen receptor-positive early breast cancer: A pragmatic, multicenter, and prospective clinical trial in China
文献摘要：
Objective: This post-approval safety study assessed the efficacy and safety of exemestane after 2?3 years of tamoxifen treatment among postmenopausal women with estrogen receptor-positive (ER+) early breast cancer in China. Methods: Enrolled patients had received 2?3 years of tamoxifen and were then switched to exemestane for completion of 5 consecutive years of adjuvant endocrine therapy. The primary endpoint was the time from enrollment to the first occurrence of locoregional/distant recurrence of the primary breast cancer, appearance of a second primary or contralateral breast cancer, or death due to any cause. Other endpoints included the proportion of patients experiencing each event, incidence rate per annum, relationships between human epidermal growth factor receptor 2 status and time to event, and relationship between disease history variables and time to event. Results: Overall, 558 patients were included in the full analysis set: 397 (71.1％) completed the study, 20 experienced an event, and 141 discontinued [47 owing to an adverse event (AE); 37 no longer willing to participate]. Median duration of treatment was 29.5 (range, 0.1?57.7) months. Median time to event was not reached. Event-free survival probability at 36 months was 91.4％ (95％ CI, 87.7％?95.1％). The event incidence over the total exposure time of exemestane therapy was 3.5 events/100 person-years (20/565). Multivariate analysis showed an association between tumor, lymph node, and metastasis stage at initial diagnosis and time to event [hazard ratio:1.532 (95％ CI, 1.129?2.080); P=0.006]. Most AEs were grade 1 or 2 in severity, with arthralgia (7.7％) being the most common treatment-related AE. Conclusions: This study supports the efficacy and safety of exemestane in postmenopausal Chinese women with ER+ breast cancer previously treated with adjuvant tamoxifen for 2?3 years. No new safety signals were identified in the Chinese population.
文献关键词：
中图分类号：
作者姓名：
Binghe Xu;Huiping Li;Zefei Jiang;Lin Gu;Jinhai Tang;Hui Xie;Yueyin Pan;Yunjiang Liu;Shude Cui;Xiaojia Wang;Li Cai;Yiqiong Zhang;Huadong Zhao;Zhimin Shao
作者机构：
Department of Medical Oncology,National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China;Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department of Breast Oncology,Peking University Cancer Hospital&Institute,Beijing 100142,China;Department of Breast Cancer,the Fifth Medical Center of Chinese PLA General Hospital,Beijing 100071,China;Department of Breast Cancer,Tianjin Cancer Institute and Hospital,Tianjin 300060,China;Department of Breast Cancer,Jiangsu Provincial Hospital,Nanjing 210029,China;Department of Breast Cancer,the First Affiliated Hospital of China University of Science and Technology,Hefei 230001,China;Department of Breast Cancer,the Fourth Hospital of Hebei Medical University,Shijiazhuang 050011,China;Department of Breast Cancer,Henan Cancer Hospital,Zhengzhou 450008,China;Department of Breast Cancer,Zhejiang Cancer Hospital,Hangzhou 310012,China;Department of Breast Cancer,Harbin Medical University Cancer Hospital,Harbin 150081,China;Department of Clinical Development,Pfizer(China)R&D Co.Ltd,Shanghai 201203,China;Department of Statistics,Pfizer(China)R&D Co.Ltd,Shanghai 201203,China;Department of Breast Surgery,Shanghai Cancer Center/Cancer Institute,Shanghai Medical College,Fudan University,Shanghai 200032,China
文献出处：
引用格式：
[1]Binghe Xu;Huiping Li;Zefei Jiang;Lin Gu;Jinhai Tang;Hui Xie;Yueyin Pan;Yunjiang Liu;Shude Cui;Xiaojia Wang;Li Cai;Yiqiong Zhang;Huadong Zhao;Zhimin Shao-.Adjuvant tamoxifen switched to exemestane treatment in postmenopausal women with estrogen receptor-positive early breast cancer: A pragmatic, multicenter, and prospective clinical trial in China)[J].中国癌症研究（英文版）,2022(06):592-601
A类：
exemestane,Enrolled
B类：
Adjuvant,tamoxifen,switched,treatment,postmenopausal,women,estrogen,receptor,positive,early,breast,cancer,pragmatic,multicenter,prospective,clinical,trial,China,Objective,This,approval,safety,study,assessed,efficacy,after,years,among,ER+,Methods,patients,had,received,were,then,completion,consecutive,adjuvant,endocrine,therapy,primary,was,from,enrollment,first,occurrence,locoregional,distant,recurrence,appearance,second,contralateral,death,due,any,cause,Other,endpoints,included,proportion,experiencing,incidence,rate,annum,relationships,between,human,epidermal,growth,status,disease,history,variables,Results,Overall,full,analysis,set,completed,experienced,discontinued,owing,adverse,longer,willing,participate,Median,duration,range,months,not,reached,Event,free,survival,probability,over,total,exposure,events,person,Multivariate,showed,association,tumor,lymph,node,metastasis,stage,initial,diagnosis,hazard,Most,AEs,grade,severity,arthralgia,being,most,common,related,Conclusions,supports,Chinese,previously,treated,No,new,signals,identified,population
AB值：
0.528592
相似文献
机标中图分类号，由域田数据科技根据网络公开资料自动分析生成，仅供学习研究参考。
